Daily Ards Research Analysis
A multicentre RCT in The BMJ shows non-invasive high frequency oscillatory ventilation (NHFOV) reduces early intubation versus NCPAP in extremely preterm infants with respiratory distress syndrome. A Nature Communications study identifies a brain–lung circuit where hypothalamic PVN CRH neurons regulate acute lung injury via a sympathetic nerve–neutrophil axis. Preclinical work demonstrates royal jelly–derived 10-HDA targets MD2/TLR4 signaling to ameliorate LPS-induced acute lung injury.
Summary
A multicentre RCT in The BMJ shows non-invasive high frequency oscillatory ventilation (NHFOV) reduces early intubation versus NCPAP in extremely preterm infants with respiratory distress syndrome. A Nature Communications study identifies a brain–lung circuit where hypothalamic PVN CRH neurons regulate acute lung injury via a sympathetic nerve–neutrophil axis. Preclinical work demonstrates royal jelly–derived 10-HDA targets MD2/TLR4 signaling to ameliorate LPS-induced acute lung injury.
Research Themes
- Non-invasive ventilation strategies in extremely preterm infants
- Neuroimmune regulation of acute lung injury
- Targeting MD2/TLR4 signaling to modulate pulmonary inflammation
Selected Articles
1. Non-invasive high frequency oscillatory ventilation for primary respiratory support in extremely preterm infants: multicentre randomised controlled trial.
In 342 extremely preterm infants with respiratory distress syndrome, NHFOV reduced the need for invasive ventilation within 72 hours compared with NCPAP (15.9% vs 27.9%; risk difference −12.0 percentage points; P=0.007). Benefits persisted through seven days, with no increase in adverse neonatal outcomes, supporting NHFOV as a primary non-invasive strategy.
Impact: This trial provides high-level evidence that a widely available non-invasive modality can reduce early intubation in extremely preterm infants, a clinically meaningful outcome with potential to influence practice.
Clinical Implications: Consider NHFOV as a primary non-invasive respiratory support option for extremely preterm infants to reduce early intubation, while monitoring for equivalent safety profiles to NCPAP.
Key Findings
- NHFOV lowered treatment failure within 72 hours versus NCPAP (15.9% vs 27.9%; risk difference −12.0 percentage points; 95% CI −20.7 to −3.4; P=0.007).
- Treatment failure within seven days was also reduced in the NHFOV group (risk difference −12.5 percentage points; 95% CI −21.9 to −3.2; P=0.008).
- No significant differences were observed in other neonatal adverse events; results were robust in sensitivity analyses accounting for sites and antenatal steroids.
Methodological Strengths
- Multicentre randomized controlled design with prespecified primary endpoint
- Prospective trial registration (ClinicalTrials.gov NCT05141435) and sensitivity analyses across sites and antenatal steroid exposure
Limitations
- Open-label design may introduce performance bias
- Conducted in Chinese NICUs; generalizability to other settings and long-term outcomes (e.g., BPD, neurodevelopment) were not established
Future Directions: Evaluate NHFOV in broader healthcare settings, assess long-term respiratory and neurodevelopmental outcomes, and optimize device settings for efficacy and safety.
OBJECTIVE: To test the hypothesis that non-invasive high frequency oscillatory ventilation (NHFOV) is more efficacious than nasal continuous positive airway pressure (NCPAP) in reducing invasive mechanical ventilation as primary respiratory support for extremely preterm infants with respiratory distress syndrome. DESIGN: A multicentre, randomised controlled trial. SETTING: Twenty tertiary neonatal intensive care units in China. PARTICIPANTS: 342 extremely preterm infants (gestational age between 24 weeks +0 day and 28 weeks +6 days) with respiratory distress syndrome were enrolled in the study between August 2022 and August 2024. INTERVENTIONS: Participants were randomly allocated to receive NCPAP or NHFOV as primary respiratory support for respiratory distress syndrome. MAIN OUTCOME MEASURES: The primary outcome was treatment failure, defined as the need for invasive mechanical ventilation within 72 hours after birth. RESULTS: Treatment failure within 72 hours occurred in 27 of` 170 infants (15.9%) in the NHFOV group and 48 of 172 infants (27.9%) in the NCPAP group (risk difference -12.0 percentage points, 95% confidence interval -20.7 to -3.4; P=0.007). Treatment failure within seven days was also lower in the NHFOV group (-12.5 percentage points, 95% confidence interval -21.9 to -3.2; P=0.008) compared with the NCPAP group. All observed associations remained significant after sensitivity analysis including study sites and antenatal steroid use. No significant differences were found in any other secondary outcomes between the two groups. CONCLUSIONS: NHFOV appeared superior to NCPAP in reducing the need for intubation when used as a primary respiratory support strategy in extremely preterm infants. Both techniques did not show significant differences in neonatal adverse events. TRIAL REGISTRATION: ClinicalTrials.gov NCT05141435.
2. Paraventricular nucleus CRH neurons regulate acute lung injury via sympathetic nerve-neutrophil axis.
Using anatomical tracing, chemogenetics, and pharmacology in male mice, the authors identify a brain–lung circuit whereby PVN CRH neurons regulate acute lung injury via a sympathetic nerve–neutrophil axis. Manipulating this circuit modulated lung inflammation, highlighting neuroimmune control as a targetable mechanism in ALI/ARDS.
Impact: Reveals a previously uncharacterized neural pathway controlling pulmonary inflammation, suggesting neuromodulatory or autonomic approaches as candidates for ARDS therapy.
Clinical Implications: While preclinical, the findings support exploration of neuromodulatory strategies (e.g., targeting hypothalamic or sympathetic pathways) to mitigate inflammation in ALI/ARDS.
Key Findings
- Identified a PVN CRH neuron–driven neural circuit that regulates lung inflammation via a sympathetic nerve–neutrophil axis in mice.
- Chemogenetic modulation of PVN CRH neurons altered the severity of acute lung injury.
- Pharmacological interventions affecting the circuit components modulated pulmonary inflammatory responses.
Methodological Strengths
- Multimodal approach combining anatomical tracing, chemogenetics, and pharmacology
- In vivo manipulation enabling causal inference on circuit function
Limitations
- Findings are limited to male mice; sex differences and human relevance remain to be established
- Translational gap and potential off-target effects of chemogenetic/pharmacologic tools
Future Directions: Validate the circuit in female and large-animal models, define efferent autonomic pathways, and assess feasibility of clinical neuromodulation to reduce lung inflammation.
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are severe conditions with high morbidity and mortality with limited effective therapies. Neuroimmune interactions play a critical role in lung homeostasis, but it remains unclear if specific brain regions regulate lung inflammation. Here, we perform anatomical tracing, chemogenetic modulation, and pharmacological interventions in male mice and identify a neural circuit from corticotropin-releasing hormone neurons in the paraventricular nucleus of the hypothalamus (CRH
3. 10-Hydroxy-2-decenoic acid ameliorates LPS-induced acute lung injury through targeting MD2-mediated inflammatory signaling pathways.
10-HDA, a royal jelly–derived fatty acid, directly binds MD2 to inhibit MD2/TLR4 signaling, suppressing both MyD88-dependent (MAPKs/NF-κB) and TRIF-dependent (TBK1/IRF3) pathways. In LPS-induced ALI, 10-HDA reduced cytokine production, neutrophil infiltration, edema, and histopathological injury in mice.
Impact: Demonstrates target engagement and mechanistic inhibition of a validated inflammatory pathway (MD2/TLR4), positioning 10-HDA as a plausible therapeutic lead for ALI/ARDS.
Clinical Implications: Supports further development of MD2-targeted therapeutics for ALI/ARDS; 10-HDA offers a natural-product scaffold for optimization. Translation requires pharmacokinetic, safety, and efficacy studies beyond LPS models.
Key Findings
- 10-HDA directly bound MD2 and disrupted MD2/TLR4 signaling, confirmed by immunoprecipitation, DARTS, and molecular docking assays.
- In LPS-induced ALI, 10-HDA reduced proinflammatory cytokines, inhibited TAK1/MAPKs/TBK1 activation and NF-κB nuclear translocation.
- 10-HDA attenuated lung histopathological injury, neutrophil infiltration, and edema in vivo.
Methodological Strengths
- Integrated in vitro macrophage assays with in vivo murine ALI model
- Multiple target-engagement methods (immunoprecipitation, DARTS, molecular docking) supporting mechanism
Limitations
- Efficacy shown primarily in LPS-induced ALI; other injury models and survival outcomes were not reported
- Pharmacokinetics, dosing, and toxicity in larger animals or humans remain undefined
Future Directions: Characterize pharmacokinetics/toxicity, test efficacy across diverse ALI/ARDS models (e.g., acid aspiration, VILI, sepsis), and optimize 10-HDA derivatives for potency and drug-likeness.
BACKGROUND: Acute lung injury (ALI) and its severe form, acute respiratory distress syndrome (ARDS), are life-threatening conditions with high mortality, characterized by excessive inflammatory responses. Lipopolysaccharide (LPS) is widely used to mimic ALI by activating myeloid differentiation factor 2 (MD2)/Toll-like receptor 4 (TLR4)-mediated inflammatory pathways. Royal jelly-derived 10-hydroxy-2-decenoic acid (10-HDA) exhibits anti-inflammatory properties, but its role in ALI remains unexplored. OBJECTIVE: This study aimed to investigate the therapeutic potential of 10-HDA against LPS-induced ALI and elucidate its underlying mechanism. METHODS: In vitro, mouse peritoneal macrophages (MPMs) were pretreated with 10-HDA before LPS stimulation. In vivo, ALI was induced in mice via intratracheal LPS, with 10-HDA administered intraperitoneally. Cytokine levels were measured via ELISA and qPCR. Signaling pathways were analyzed by Western blot and immunofluorescence. Lung injury, inflammatory cell infiltration, and edema were assessed via histopathology, BALF analysis, and wet/dry ratio. Immunoprecipitation, molecular docking, and drug affinity-responsive target stability (DARTS) assays were used to identify the interaction between 10-HDA and MD2. RESULTS: 10-HDA significantly suppressed LPS-induced proinflammatory cytokine secretion in MPMs and ALI mice, and inhibited phosphorylation of TAK1, MAPKs, TBK1 and NF-κB nuclear translocation. It attenuated lung histopathological damage, neutrophil infiltration, and edema. Mechanistically, 10-HDA disrupted MD2/TLR4-mediated inflammatory pathways by directly binding MD2, as confirmed by immunoprecipitation, DARTS, and molecular docking. CONCLUSION: 10-HDA alleviates LPS-induced ALI by targeting MD2 to block TLR4 signaling, thereby suppressing both MyD88-dependent (MAPKs/NF-κB) and TRIF-dependent (TBK1/IRF3) pathways. These findings highlight 10-HDA as a promising therapeutic candidate for ALI/ARDS.